Covered recipient · General Payments record
JOEL CHRISTOPHER JOYCE
Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$2,376.00
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,376.00 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $2,376.00 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOEL CHRISTOPHER JOYCE
NPI 1700045713 · CMS profile ID 77679
Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology
SKOKIE, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1700045713?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700045713?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700045713?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1700045713?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $2,376.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $2,376.00 | 07/20/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744016853 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,750.00 | 4 |
| PY2025 | Principal investigator | $694,810.55 | 184 |
| PY2024 | Recipient | $7,148.03 | 20 |
| PY2024 | Principal investigator | $657,792.45 | 167 |
| PY2023 | Recipient | $3,281.97 | 14 |
| PY2023 | Principal investigator | $421,779.06 | 92 |
| PY2022 | Recipient | $1,517.38 | 3 |
| PY2022 | Principal investigator | $234,287.76 | 66 |
| PY2021 | Principal investigator | $111,180.61 | 56 |
| PY2020 | Principal investigator | $343,493.78 | 70 |
| PY2019 | Principal investigator | $4,975.53 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
188 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140249 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140253 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140257 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140261 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140265 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140269 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140271 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140275 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140280 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140284 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140288 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140292 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140656 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140660 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140663 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140667 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140671 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 12/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140675 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,603.70 | 12/22/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226140647 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,344.00 | 12/08/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140637 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,021.00 | 12/08/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140643 |
| Principal investigator 1 | Incyte Corporation | $3,844.80 | 12/04/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532230 |
| Principal investigator 1 | Incyte Corporation | $5,149.50 | 12/04/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532234 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,349.40 | 11/17/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226140631 |
| Principal investigator 1 | Incyte Corporation | $5,724.00 | 11/14/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532225 |
| Principal investigator 1 | ABBVIE INC. | $1,389.50 | 11/04/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417181 |
| Recipient | GENZYME CORPORATION | $500.00 | 10/24/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226080341 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,849.00 | 10/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140560 |
| Principal investigator 1 | Incyte Corporation | $1,879.20 | 10/16/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532218 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,181.20 | 10/14/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226140556 |
| Principal investigator 1 | ABBVIE INC. | $1,816.48 | 10/09/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417153 |
| Principal investigator 1 | Incyte Corporation | $4,209.30 | 10/09/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532221 |
| Principal investigator 1 | Incyte Corporation | $2,330.10 | 09/23/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532214 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $283.00 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140567 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140572 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140575 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140580 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140585 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140589 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140593 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140596 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140600 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140611 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140615 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140619 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140622 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140625 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 09/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140628 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/17/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226080333 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,125.20 | 09/15/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226140548 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,482.00 | 09/15/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140552 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,470.00 | 09/04/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140603 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 09/03/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486801 |
| Principal investigator 1 | Incyte Corporation | $5,400.00 | 09/03/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486808 |
| Principal investigator 1 | Incyte Corporation | $7,192.10 | 08/26/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240486981 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $20,678.38 | 08/25/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226140536 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 08/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486825 |
| Principal investigator 1 | Incyte Corporation | $2,194.20 | 08/14/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240486986 |
| Principal investigator 1 | Incyte Corporation | $2,208.60 | 08/13/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486830 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,372.70 | 08/11/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226140532 |
| Principal investigator 1 | ABBVIE INC. | $518.60 | 08/05/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 07/28/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175213817 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 07/28/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175213949 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 07/28/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175214088 |
| Principal investigator 1 | Incyte Corporation | $4,388.40 | 07/22/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532210 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,250.00 | 07/17/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175213697 |
| Principal investigator 1 | Incyte Corporation | $2,027.70 | 07/16/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486812 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,785.20 | 07/14/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226140437 |
| Principal investigator 1 | Incyte Corporation | $6,481.80 | 07/10/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532201 |
| Principal investigator 1 | Incyte Corporation | $990.00 | 07/10/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532205 |
| Principal investigator 1 | Incyte Corporation | $242.00 | 07/07/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486818 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $132.00 | 07/02/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226140441 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,962.00 | 07/02/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140524 |
| Principal investigator 1 | Incyte Corporation | $2,027.70 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486728 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140425 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140427 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140430 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140433 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140443 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140447 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140451 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140457 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140459 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140462 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140467 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140470 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140473 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140476 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140480 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140484 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140488 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $283.00 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140492 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140496 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140500 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140504 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140508 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140512 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140516 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 06/20/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140520 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,738.40 | 06/16/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226140421 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 06/13/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486702 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 06/13/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486708 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 06/13/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486733 |
| Principal investigator 1 | Incyte Corporation | $569.00 | 06/13/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486746 |
| Principal investigator 1 | Incyte Corporation | $264.00 | 06/13/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486758 |
| Principal investigator 1 | Incyte Corporation | $484.00 | 06/13/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486789 |
| Principal investigator 1 | Incyte Corporation | $6,481.80 | 06/12/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532190 |
| Principal investigator 1 | Incyte Corporation | $99.00 | 06/12/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532194 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,768.00 | 06/09/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140417 |
| Principal investigator 1 | Incyte Corporation | $132.00 | 06/06/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486752 |
| Principal investigator 1 | Incyte Corporation | $119.00 | 06/06/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486782 |
| Principal investigator 1 | Incyte Corporation | $165.00 | 06/06/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486795 |
| Principal investigator 1 | Incyte Corporation | $6,481.80 | 06/05/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532197 |
| Principal investigator 1 | Amgen Inc. | $4,575.00 | 06/03/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) | No dispute reported | 06/30/2026 | 1246637676 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 06/03/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486768 |
| Recipient | GENZYME CORPORATION | $500.00 | 05/29/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226080329 |
| Recipient | GENZYME CORPORATION | $250.00 | 05/29/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226080337 |
| Principal investigator 1 | Eli Lilly and Company | $6,307.98 | 05/28/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187872363 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,650.00 | 05/27/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226140413 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,813.64 | 05/15/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175214080 |
| Principal investigator 1 | Incyte Corporation | $2,573.00 | 05/14/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486714 |
| Principal investigator 1 | Incyte Corporation | $1,697.60 | 05/14/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486719 |
| Principal investigator 1 | Incyte Corporation | $2,537.00 | 05/14/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486740 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,900.00 | 05/12/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226140409 |
| Principal investigator 1 | ABBVIE INC. | $1,816.48 | 05/06/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417084 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 05/01/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,813.64 | 04/28/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175213782 |
| Principal investigator 1 | Incyte Corporation | $2,087.10 | 04/16/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486777 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $75,417.00 | 04/14/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140405 |
| Principal investigator 1 | Incyte Corporation | $2,395.80 | 04/11/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486763 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 04/08/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532168 |
| Principal investigator 1 | ABBVIE INC. | $2,043.68 | 04/03/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417077 |
| Principal investigator 1 | Incyte Corporation | $3,500.00 | 04/01/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532164 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 04/01/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532173 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 04/01/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532177 |
| Principal investigator 1 | Incyte Corporation | $13,200.00 | 04/01/2025 | Non-covered Recipient Entity ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240532181 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140330 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140333 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140340 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140343 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140347 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140350 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140353 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140356 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140359 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140362 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140364 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140368 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $897.35 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140372 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140374 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140382 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140387 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140392 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140397 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $394.10 | 03/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226140401 |
| Principal investigator 1 | Incyte Corporation | $2,253.00 | 03/19/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486622 |
| Principal investigator 1 | Incyte Corporation | $2,319.00 | 03/19/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486629 |
| Principal investigator 1 | Incyte Corporation | $1,751.40 | 03/19/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486634 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,054.25 | 03/10/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226140296 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,082.00 | 03/10/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226140299 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,636.00 | 03/04/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140303 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,400.00 | 03/04/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226140308 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 03/03/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486665 |
| Principal investigator 1 | Incyte Corporation | $3,383.20 | 03/03/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486673 |
| Principal investigator 1 | Incyte Corporation | $4,229.00 | 03/03/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486678 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,395.55 | 03/03/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175213868 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,260.00 | 02/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226140321 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,178.70 | 02/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226140326 |
| Principal investigator 1 | Incyte Corporation | $3,751.00 | 02/21/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486603 |
| Principal investigator 1 | Incyte Corporation | $2,573.00 | 02/21/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486610 |
| Principal investigator 1 | Incyte Corporation | $1,395.30 | 02/21/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486614 |
| Principal investigator 1 | Incyte Corporation | $472.61 | 02/12/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240486697 |
| Principal investigator 1 | Amgen Inc. | $82,848.01 | 02/05/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246637672 |
| Principal investigator 1 | Incyte Corporation | $4.25 | 02/05/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486646 |
| Principal investigator 1 | Incyte Corporation | $52.48 | 02/05/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486653 |
| Principal investigator 1 | Incyte Corporation | $77.75 | 02/05/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486659 |
| Principal investigator 1 | Incyte Corporation | $93.30 | 02/05/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486684 |
| Principal investigator 1 | Janssen Research & Development, LLC | $966.00 | 02/04/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175214045 |
| Principal investigator 1 | Incyte Corporation | $1,945.20 | 01/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486583 |
| Principal investigator 1 | Incyte Corporation | $2,253.00 | 01/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486589 |
| Principal investigator 1 | Incyte Corporation | $2,253.00 | 01/24/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486597 |
| Principal investigator 1 | Incyte Corporation | $2,694.33 | 01/23/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240486691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,768.27 | 01/16/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175213746 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 01/08/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240486640 |
| Principal investigator 1 | Amgen Inc. | $15,189.41 | 01/06/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246637678 |
| Principal investigator 1 | ABBVIE INC. | $2,175.98 | 01/02/2025 | Covered Recipient Teaching Hospital NORTHSHORE UNIVERSITY HEALTHSYSTEM | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417037 |
| Principal investigator 1 | Amgen Inc. | $119,750.63 | 01/02/2025 | Covered Recipient Teaching Hospital Northshore University Healthsystem | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246637670 |